A reminder that we do not meet in July or August. Our next scheduled group meeting will be Tuesday, September 13th, 2022. Further details will follow. Enjoy your summer! If you need someone to talk to, please reach out to us at winexpcsg@gmail.com
A request from The Canadian Cancer Society:
Hello,
My name is Sasha Frost and I am the Sr Advocacy Specialist, Public Engagement for the Canadian Cancer Society. To better inform the Canadian Agency for Drugs and Technologies in Health (CADTH), the Canadian Cancer Society has launched a survey to understand the experience of people impacted by high-risk non-metastatic prostate cancer. High-risk means there is a greater chance of the cancer spreading. Non-metastatic means the cancer has not spread to other parts of the body. We are also seeking feedback on the advantages and disadvantages of the drug abiraterone acetate from those who have had experience with it. The patient or caregiver does not have to have experience with abiraterone acetate to complete the survey, as information on their satisfaction with current treatments is valuable on its own.
Patients living with and beyond cancer as well as caregivers have first-hand experience of life with cancer and are well-positioned to describe the benefits and drawbacks of currently available treatments and help assess new treatments. Patient and caregiver feedback is critical and will help CADTH develop drug funding recommendations in Canada. This survey will help CADTH decide if they should recommend that abiraterone acetate in combination with prednisolone should be covered in Canada on public drug plans for people with high-risk non-metastatic prostate cancer.
If you have cancer patients or their caregivers in your network, we would greatly appreciate if you would share this new online survey. The survey is available in French and English. Please feel free to share this opportunity with patients, caregivers or other networks you are aware of to ensure patient voices are heard.
The survey will take about 15-20 minutes to complete, and the deadline for completion is July 31, 2022. Participation is completely voluntary and responses are anonymous. For more information, view our privacy policy. For more information about providing feedback on cancer drugs, please visit our page dedicated to this subject on cancer.ca. Please note that this survey is not to endorse any specific drug or treatment and is for evaluation only.
We will also be accepting testimonials from those who have high-risk non-metastatic prostate cancer who have tried abiraterone acetate outlining their experience with this medication. If you have someone in your network in this circumstance that would like to submit a testimonial, please let me know.
Thank you,
| Sasha Frost (She/Her) Sr Advocacy Specialist (Public Engagement) / spécialiste principale, Défense de l’intérêt public (engagement public) Canadian Cancer Society / Société canadienne du cancer |
E Sasha.Frost@cancer.ca
T (905) 259-2721
55 St Clair Avenue West, Suite 300 / 55, avenue St. Clair Ouest, bureau 300
Toronto, Ontario M4V 2Y7
| It’s hard to believe it’s already July! Wishing you all a wonderful summer no matter where you’re enjoying it. Stay cool, wear your sunscreen, and don’t burn your BBQing! Note that many support groups are taking a break for August; please check the support group calendar for the most up to date meeting info. |
 |
| Prostate Cancer Support Coast to Coast TUESDAY, JULY 26TH, 2022 | 11AM PT (2PM ET) |
| Dr. David Stewart, medical oncologist is the authour of new book, A Short Primer on Why Cancer Still Sucks. He has published more than 340 peer-reviewed publications. He has also published several Op-Eds in the lay press dealing predominantly with patient access to care, including an opinion piece published in the Ottawa Citizen 2022/06/21. His areas of research interest have included (among others) resistance mechanisms to anticancer agents and resistance modulation, pharmacology and pharmacogenetics of platinums and other anticancer agents, new drug development and predictive biomarkers in lung cancer, the negative impact of dysfunctional regulation and clinical trial designs on the rate of clinical research progress, and the huge costs of this clinical research dysfunction in terms of increased health care costs and in terms of lives prematurely lost.Our monthly Coast to Coast support group meeting brings together prostate cancer patients and their support people across the country for an expert speaker presentation on varying topics each month, an opportunity for Q&A, and small group support group sessions via Zoom breakout rooms. |
| Partners in Prostate – Partner-Only Support Group WEDNESDAY, JULY 27TH, 2022 | 6PM PT (9PM ET) Prostate cancer is commonly referred to as a couple’s disease, due to its impact on not just prostate cancer patients, but their partners as well. Join us at this partners-only meeting for a chance to share about your journey and learn from the experience of others going through this too. First time attendees will be given priority to share. Can’t make it to a meeting? Check out the Partners in Prostate forum where you can chat with other partners 24/7. Register now |
| Prostate Cancer Support Toronto WEDNESDAY, JULY 27TH, 2022 4PM PT (7PM ET) |
 Dr. Di (Maria) Jiang MD, MSc, FRCPC is an Assistant Professor, Clinician Investigator in the Department of Medicine at the University of Toronto and a Medical Oncologist in the Genitourinary group at Princess Margaret Cancer Center. She will be speaking on the Management of Advanced Prostate Cancer. This session will feature a focus on the current standard of metastatic prostate cancer care and promising new therapies and clinical trials that are on the horizon. As well, it is hoped that a few myths about metastatic prostate cancer will be debunked along the way! |
 |
| Astellas announced reimbursement program for XTANDI (enzalutamide) for mCSPC (metastatic castrate sensitive prostate cancer) patients. Read more here. |
| Click here for a list of research opportunities and clinical trials that have been shared with us this month. |
| Prostatepedia is a free publication that consolidates the latest research in prostate cancer. The July 15th edition is available here. |
| The Life on ADT (Androgen Deprivation Therapy) online educational program’s next session will be at 3:00 pm Pacific/6 pm Eastern on July 18th and August 17th. More information available here. |
